## Diego Albani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5770103/publications.pdf

Version: 2024-02-01

		70961	26548
167	13,416	41	107
papers	citations	h-index	g-index
191	191	191	27976
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Identifying the Common Genetic Basis of Antidepressant Response. Biological Psychiatry Global Open Science, 2022, 2, 115-126.	1.0	31
2	A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response. European Neuropsychopharmacology, 2022, 55, 86-95.	0.3	19
3	Using integrated meta-omics to appreciate the role of the gut microbiota in epilepsy. Neurobiology of Disease, 2022, 164, 105614.	2.1	5
4	The microbiotaâ€gutâ€brain axis and epilepsy from a multidisciplinary perspective: Clinical evidence and technological solutions for improvement of in vitro preclinical models. Bioengineering and Translational Medicine, 2022, 7, .	3.9	10
5	Metabolizing status of CYP2C19 in response and side effects to medications for depression: Results from a naturalistic study. European Neuropsychopharmacology, 2022, 56, 100-111.	0.3	5
6	Polygenic risk scores for neuropsychiatric, inflammatory, and cardioâ€metabolic traits highlight possible genetic overlap with suicide attempt and treatmentâ€emergent suicidal ideation. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2022, 189, 74-85.	1.1	8
7	Induced pluripotent stem cell-based organ-on-a-chip as personalized drug screening tools: A focus on neurodegenerative disorders. Journal of Tissue Engineering, 2022, 13, 204173142210953.	2.3	14
8	Drug repositioning for treatment-resistant depression: Hypotheses from a pharmacogenomic study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 104, 110050.	<b>2.</b> 5	21
9	Cost-effectiveness of genetic and clinical predictors for choosing combined psychotherapy and pharmacotherapy in major depression. Journal of Affective Disorders, 2021, 279, 722-729.	2.0	7
10	Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 108, 110170.	2.5	36
11	Graphene based electrochemical immunosensor for the ultra-sensitive label free detection of Alzheimer's beta amyloid peptides Al²(1–42). Nanoscale Advances, 2021, 3, 2295-2304.	2.2	21
12	The nuclear import of the transcription factor MyoD is reduced in mesenchymal stem cells grown in a 3D micro-engineered niche. Scientific Reports, 2021, 11, 3021.	1.6	13
13	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	9.4	198
14	Microbiotaâ€Host Immunity Communication in Neurodegenerative Disorders: Bioengineering Challenges for In Vitro Modeling. Advanced Healthcare Materials, 2021, 10, e2002043.	3.9	18
15	Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. Nature Genetics, 2021, 53, 817-829.	9.4	629
16	Technological tools and strategies for culturing human gut microbiota in engineered in vitro models. Biotechnology and Bioengineering, 2021, 118, 2886-2905.	1.7	20
17	Genome-wide association identifies the first risk loci for psychosis in Alzheimer disease. Molecular Psychiatry, 2021, 26, 5797-5811.	4.1	30
18	Convergent and Discriminant Validity of Default Mode Network and Limbic Network Perfusion in Amnestic Mild Cognitive Impairment Patients. Journal of Alzheimer's Disease, 2021, 82, 1797-1808.	1.2	4

#	Article	IF	CITATIONS
19	Research Domain Criteria (RDoC): A Perspective to Probe the Biological Background behind Treatment Efficacy in Depression. Current Medicinal Chemistry, 2021, 28, 4296-4320.	1.2	1
20	A Conformation Variant of p53 Combined with Machine Learning Identifies Alzheimer Disease in Preclinical and Prodromal Stages. Journal of Personalized Medicine, 2021, 11, 14.	1.1	19
21	Microbiological-Chemical Sourced Chondroitin Sulfates Protect Neuroblastoma SH-SY5Y Cells against Oxidative Stress and Are Suitable for Hydrogel-Based Controlled Release. Antioxidants, 2021, 10, 1816.	2.2	3
22	Psychiatric disorders and SLC6A4 gene variants: possible effects on alcohol dependence and alzheimer's disease. Molecular Biology Reports, 2020, 47, 191-200.	1.0	6
23	The Genetics of the Mood Disorder Spectrum: Genome-wide Association Analyses of More Than 185,000 Cases and 439,000 Controls. Biological Psychiatry, 2020, 88, 169-184.	0.7	137
24	CSF cutoffs for MCI due to AD depend on APOEε4 carrier status. Neurobiology of Aging, 2020, 89, 55-62.	1.5	11
25	3D brain tissue physiological model with co-cultured primary neurons and glial cells in hydrogels. Journal of Tissue Engineering, 2020, 11, 204173142096398.	2.3	14
26	A miniaturized hydrogel-based <i>in vitro</i> model for dynamic culturing of human cells overexpressing beta-amyloid precursor protein. Journal of Tissue Engineering, 2020, 11, 204173142094563.	2.3	15
27	Human Gut-Microbiota Interaction in Neurodegenerative Disorders and Current Engineered Tools for Its Modeling. Frontiers in Cellular and Infection Microbiology, 2020, 10, 297.	1.8	37
28	A polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotyping. Translational Psychiatry, 2020, 10, 50.	2.4	33
29	Genetic variants associated with psychotic symptoms across psychiatric disorders. Neuroscience Letters, 2020, 720, 134754.	1.0	9
30	Increased transcription of transglutaminase 1 mediates neuronal death in in vitro models of neuronal stress and $\hat{Al^2}1\hat{a}\in {}^{\!\!\!\!\!\!\!\!\!^{''}}42$ -mediated toxicity. Neurobiology of Disease, 2020, 140, 104849.	2.1	10
31	Predicting and Tracking Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease: Structural Brain Biomarkers. Journal of Alzheimer's Disease, 2019, 69, 3-14.	1.2	18
32	Genetic basis of psychopathological dimensions shared between schizophrenia and bipolar disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 89, 23-29.	2.5	13
33	An Organ-On-A-Chip Engineered Platform to Study the Microbiota–Gut–Brain Axis in Neurodegeneration. Trends in Molecular Medicine, 2019, 25, 737-740.	3.5	55
34	Merging memantine and ferulic acid to probe connections between NMDA receptors, oxidative stress and amyloid- $\hat{l}^2$ peptide in Alzheimer's disease. European Journal of Medicinal Chemistry, 2019, 180, 111-120.	2.6	45
35	Genetic variation across RNA metabolism and cell death gene networks is implicated in the semantic variant of primary progressive aphasia. Scientific Reports, 2019, 9, 10854.	1.6	9
36	Hydrogel-based delivery of Tat-fused protein Hsp70 protects dopaminergic cells in vitro and in a mouse model of Parkinson's disease. NPG Asia Materials, 2019, 11, .	3.8	28

#	Article	IF	CITATIONS
37	Microbiota-gut brain axis involvement in neuropsychiatric disorders. Expert Review of Neurotherapeutics, 2019, 19, 1037-1050.	1.4	116
38	Mechanical regulation of nucleocytoplasmic translocation in mesenchymal stem cells: characterization and methods for investigation. Biophysical Reviews, 2019, 11, 817-831.	1.5	22
39	F105AN EXOME SEQUENCING STUDY IN TREATMENT-RESISTANT DEPRESSION. European Neuropsychopharmacology, 2019, 29, S1166-S1167.	0.3	0
40	M67 PSYCHIATRIC DISORDERS AND SLC6A4 GENE VARIANTS: POSSIBLE MODULATION OF ALCOHOL DEPENDENCE AND ALZHEIMER'S DISEASE. European Neuropsychopharmacology, 2019, 29, S202-S203.	0.3	0
41	Advanced Organ-on-a-Chip Devices to Investigate Liver Multi-Organ Communication: Focus on Gut, Microbiota and Brain. Bioengineering, 2019, 6, 91.	1.6	26
42	Alzheimer's Disease and Neurotransmission Gene Variants: Focus on Their Effects on Psychiatric Comorbidities and Inflammatory Parameters. Neuropsychobiology, 2019, 78, 79-85.	0.9	9
43	WHOLE EXOME SEQUENCING REVEALS RISK FACTORS IN TREATMENT RESISTANT DEPRESSION. European Neuropsychopharmacology, 2019, 29, S934-S935.	0.3	0
44	Genome-wide association study identifies 30 loci associated with bipolar disorder. Nature Genetics, 2019, 51, 793-803.	9.4	1,191
45	Gene expression meta-analysis of Parkinson's disease and its relationship with Alzheimer's disease. Molecular Brain, 2019, 12, 16.	1.3	52
46	Biomarker Matrix to Track Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 69, 49-58.	1.2	8
47	M74 HIGHER POLYGENIC RISK SCORES FOR SCHIZOPHRENIA MAY BE SUGGESTIVE OF NON-RESPONSE TO DRUGS FOR DEPRESSION IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER. European Neuropsychopharmacology, 2019, 29, S206-S207.	0.3	0
48	Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders. Cell, 2019, 179, 1469-1482.e11.	13.5	935
49	Plasma AÎ <sup>2</sup> 42 as a Biomarker of Prodromal Alzheimer's Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study. Journal of Alzheimer's Disease, 2019, 69, 37-48.	1.2	23
50	Corrected QT Interval Prolongation in Psychopharmacological Treatment and Its Modulation by Genetic Variation. Neuropsychobiology, 2019, 77, 67-72.	0.9	13
51	Two-Year Longitudinal Monitoring of Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease Using Topographical Biomarkers Derived from Functional Magnetic Resonance Imaging and Electroencephalographic Activity. Journal of Alzheimer's Disease, 2019, 69, 15-35.	1.2	34
52	Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples. British Journal of Psychiatry, 2019, 214, 36-41.	1.7	44
53	Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia. Nature Medicine, 2019, 25, 152-164.	15.2	111
54	Organ-On-A-Chip in vitro Models of the Brain and the Blood-Brain Barrier and Their Value to Study the Microbiota-Gut-Brain Axis in Neurodegeneration. Frontiers in Bioengineering and Biotechnology, 2019, 7, 435.	2.0	73

#	Article	IF	CITATIONS
55	Alpha-synuclein oligomers impair memory through glial cell activation and via Toll-like receptor 2. Brain, Behavior, and Immunity, 2018, 69, 591-602.	2.0	55
56	CXCR4 involvement in neurodegenerative diseases. Translational Psychiatry, 2018, 8, 73.	2.4	66
57	Hot Genes in Schizophrenia: How Clinical Datasets Could Help to Refine their Role. Journal of Molecular Neuroscience, 2018, 64, 273-286.	1.1	5
58	Pleiotropic genes in psychiatry: Calcium channels and the stress-related FKBP5 gene in antidepressant resistance. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 81, 203-210.	2.5	31
59	Genetic Variants Within Molecular Targets of Antipsychotic Treatment: Effects on Treatment Response, Schizophrenia Risk, and Psychopathological Features. Journal of Molecular Neuroscience, 2018, 64, 62-74.	1.1	3
60	Asymptomatic Carriers of Presenilin-1 E318G Variant Show no Cerebrospinal Fluid Biochemical Signs Suggestive of Alzheimer's disease in a Family with Late-onset Dementia. Current Alzheimer Research, 2018, 16, 1-7.	0.7	4
61	The serotonin transporter and the activity regulated cytoskeletonâ€associated protein genes in antidepressant response and resistance: <scp>5â€HTTLPR</scp> and other variants. Human Psychopharmacology, 2018, 33, e2682.	0.7	7
62	Systematic Analysis and Biomarker Study for Alzheimer's Disease. Scientific Reports, 2018, 8, 17394.	1.6	62
63	Exome sequencing in an Italian family with Alzheimer's disease points to a role for seizure-related gene 6 (SEZ6) rare variant R615H. Alzheimer's Research and Therapy, 2018, 10, 106.	3.0	15
64	Genomic Dissection of Bipolar Disorder and Schizophrenia, Including 28 Subphenotypes. Cell, 2018, 173, 1705-1715.e16.	13.5	623
65	Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies. PLoS Medicine, 2018, 15, e1002487.	3.9	111
66	Genetic architecture of sporadic frontotemporal dementia and overlap with Alzheimer's and Parkinson's diseases. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 152-164.	0.9	107
67	Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance. European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 723-735.	1.8	21
68	Association between CSF biomarkers, hippocampal volume and cognitive function in patients with amnestic mild cognitive impairment (MCI). Neurobiology of Aging, 2017, 53, 1-10.	1.5	59
69	Electrocardiogram Alterations Associated With Psychotropic Drug Use and CACNA1C Gene Variants in Three Independent Samples. Basic and Clinical Pharmacology and Toxicology, 2017, 120, 482-490.	1.2	10
70	Genetic Variants Within Key Nodes of the Cascade of Antipsychotic Mechanisms: Effects on Antipsychotic Response and Schizophrenia Psychopathology in a Naturalistic Treatment Setting in Two Independent Korean and Italian Samples. Advances in Therapy, 2017, 34, 1482-1497.	1.3	3
71	Secretome released from hydrogel-embedded adipose mesenchymal stem cells protects against the Parkinson $\hat{a} \in \mathbb{N}$ s disease related toxin 6-hydroxydopamine. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 121, 113-120.	2.0	50
72	Recombinant human Tat-Hsp70-2: A tool for neuroprotection. Protein Expression and Purification, 2017, 138, 18-24.	0.6	10

#	Article	IF	CITATIONS
73	[P4–157]: CSF BIOMARKERS AND EFFECT OF APOLIPOPROTEIN E GENOTYPE, AGE AND SEX ON CUTâ€OFF DERIVATION IN MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P1319.	0.4	4
74	Potential genes behind the difference between bipolar I and bipolar II disorder. European Neuropsychopharmacology, 2017, 27, S836-S837.	0.3	0
75	Association between CACNA1C gene rs1034936 polymorphism and alcoholism in bipolar disorder. European Neuropsychopharmacology, 2017, 27, S1057-S1058.	0.3	0
76	Sirtuin Modulation as Novel Neuroprotective Strategy for Alzheimer's Disease. , 2017, , 149-173.		2
77	Frontotemporal Lobar Degeneration and MicroRNAs. Frontiers in Aging Neuroscience, 2016, 8, 17.	1.7	22
78	Ultrathin electrospun PANI nanofibers for neuronal tissue engineering. Journal of Applied Polymer Science, 2016, 133, .	1.3	13
79	Clinical and biomarker profiling of prodromal Alzheimer's disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a  European <scp>ADNI</scp> study'. Journal of Internal Medicine, 2016, 279, 576-591.	2.7	64
80	CHRNA7 Gene and Response to Cholinesterase Inhibitors in an Italian Cohort of Alzheimer's Disease Patients. Journal of Alzheimer's Disease, 2016, 52, 1203-1208.	1.2	18
81	ECG alterations associated with psychotropic drug use in clinical settings: clinical and genetic predictors. European Neuropsychopharmacology, 2016, 26, S240-S241.	0.3	0
82	Role of neurodevelopment involved genes in psychiatric comorbidities and modulation of inflammatory processes in Alzheimer's disease. Journal of the Neurological Sciences, 2016, 370, 162-166.	0.3	12
83	Association between Sirtuin 1 Gene rs10997870 Polymorphism and Suicide Behaviors in Bipolar Disorder. Neuropsychobiology, 2016, 74, 1-7.	0.9	15
84	Sirtuin 2 Inhibition Improves Cognitive Performance and Acts on Amyloid-β Protein Precursor Processing in Two Alzheimer's Disease Mouse Models. Journal of Alzheimer's Disease, 2016, 53, 1193-1207.	1.2	61
85	The role of single-nucleotide variants of the energy metabolism-linked genes <i>SIRT3</i> , <i>PPARGC1A</i> and <i>APOE</i> in amyotrophic lateral sclerosis risk. Genes and Genetic Systems, 2016, 91, 301-309.	0.2	10
86	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	4.3	4,701
87	Clinical and genetic factors associated with suicide in mood disorder patients. European Archives of Psychiatry and Clinical Neuroscience, 2016, 266, 181-193.	1.8	32
88	Loss of exosomes in progranulin-associated frontotemporal dementia. Neurobiology of Aging, 2016, 40, 41-49.	1.5	47
89	SORL1 Gene is Associated with the Conversion from Mild Cognitive Impairment to Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 46, 771-776.	1.2	14
90	Genetics of psychotropic medication induced side effects in two independent samples of bipolar patients. Journal of Neural Transmission, 2015, 122, 43-58.	1.4	14

#	Article	IF	Citations
91	The Parkinson's Disease-Related Protein DJ-1 Protects Dopaminergic Neurons in vivo and Cultured Cells from Alpha-Synuclein and 6-Hydroxydopamine Toxicity. Neurodegenerative Diseases, 2015, 15, 13-23.	0.8	32
92	Cross-linked poly(acrylic acids) microgels and agarose as semi-interpenetrating networks for resveratrol release. Journal of Materials Science: Materials in Medicine, 2015, 26, 5328.	1.7	11
93	Neuronal cell adhesion genes and antidepressant response in three independent samples. Pharmacogenomics Journal, 2015, 15, 538-548.	0.9	34
94	The SIRT1 promoter polymorphic site rs12778366 increases IL-6 related human mortality in the prospective study "Treviso Longeva (TRELONG)". International Journal of Molecular Epidemiology and Genetics, 2015, 6, 20-6.	0.4	4
95	Melatonin and the Charlson Comorbidity Index (CCI): The Treviso Longeva (Trelong) Study. International Journal of Biological Markers, 2014, 29, 253-260.	0.7	7
96	Environmental Enrichment Lessens Cognitive Decline in APP23 Mice Without Affecting Brain Sirtuin Expression. Journal of Alzheimer's Disease, 2014, 42, 851-864.	1.2	30
97	Genes involved in neuroplasticity and stressful life events act on the short-term response to antidepressant treatment: a complex interplay between genetics and environment. Human Psychopharmacology, 2014, 29, 388-391.	0.7	11
98	Stress Impairs Synaptic Plasticity in Triple-Transgenic Alzheimer's Disease Mice: Rescue by Ryanodine. Neurodegenerative Diseases, 2014, 13, 135-138.	0.8	15
99	Modulation of human longevity by SIRT3 single nucleotide polymorphisms in the prospective study "Treviso Longeva (TRELONG)― Age, 2014, 36, 469-478.	3.0	63
100	PPP3CC gene: a putative modulator of antidepressant response through the B-cell receptor signaling pathway. Pharmacogenomics Journal, 2014, 14, 463-472.	0.9	41
101	P.1.014 PPP3CC: a new candidate gene in antidepressant response. European Neuropsychopharmacology, 2014, 24, S14-S15.	0.3	0
102	Evaluation of the role of MAPK1 and CREB1 polymorphisms on treatment resistance, response and remission in mood disorder patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 44, 271-278.	2.5	38
103	Body mass index, lifestyles, physical performance and cognitive decline: The "Treviso Longeva (Trelong)―study. Journal of Nutrition, Health and Aging, 2013, 17, 378-384.	1.5	57
104	One single method to produce native and Tat-fused recombinant human $\hat{l}_{\pm}$ -synuclein in Escherichia coli. BMC Biotechnology, 2013, 13, 32.	1.7	18
105	Association between Sirtuin 2 gene rs10410544 polymorphism and depression in Alzheimer's disease in two independent European samples. Journal of Neural Transmission, 2013, 120, 1709-1715.	1.4	30
106	P.5.b.002 Association between sirtuin 2 gene rs10410544 polymorphism and depression in Alzheimer's disease in two independent European samples. European Neuropsychopharmacology, 2013, 23, S540-S541.	0.3	0
107	Systematic Analysis of Injectable Materials and 3D Rapid Prototyped Magnetic Scaffolds: From CNS Applications to Soft and Hard Tissue Repair/Regeneration. Procedia Engineering, 2013, 59, 233-239.	1.2	60
108	P.2.f.014 PPP3CC gene in antidepressant response: results from three independent samples. European Neuropsychopharmacology, 2013, 23, S403.	0.3	0

#	Article	IF	CITATIONS
109	Pharmacogenomics in Alzheimer's disease: a genome-wide association study of response to cholinesterase inhibitors. Neurobiology of Aging, 2013, 34, 1711.e7-1711.e13.	1.5	43
110	The <i>SIRT2</i> polymorphism rs10410544 and risk of Alzheimer's disease in two Caucasian caseâ€"control cohorts. Alzheimer's and Dementia, 2013, 9, 392-399.	0.4	40
111	Impact of 5-HTTLPR Polymorphism on Alexithymia in Alcoholic Patients After Detoxification Treatment. Journal of Addiction Medicine, 2013, 7, 372-373.	1.4	4
112	Development and Analysis of Semi-Interpenetrating Polymer Networks for Brain Injection in Neurodegenerative Disorders. International Journal of Artificial Organs, 2013, 36, 762-774.	0.7	10
113	C9ORF72 Hexanucleotide Repeat Number in Frontotemporal Lobar Degeneration: A Genotype-Phenotype Correlation Study. Journal of Alzheimer's Disease, 2013, 38, 799-808.	1.2	43
114	Hydrogel-Based Nanocomposites and Mesenchymal Stem Cells: A Promising Synergistic Strategy for Neurodegenerative Disorders Therapy. Scientific World Journal, The, 2013, 2013, 1-9.	0.8	25
115	Effects of SORL1 Gene on Alzheimer's Disease. Focus on Gender, Neuropsychiatric Symptoms and Pro-Inflammatory Cytokines. Current Alzheimer Research, 2013, 10, 154-164.	0.7	12
116	Synergism Between Resveratrol and Crocin for Protection of Human Neuroblastoma SHSY-5Y Cells against Oxidative Stress. Planta Medica, 2013, 79, .	0.7	0
117	Association of SORL1 Alleles with Late-Onset Alzheimer's Disease. Findings from the GIGAS_LOAD Study and Mega-Analysis. Current Alzheimer Research, 2012, 9, 491-499.	0.7	13
118	Body Mass Index, Cognition, Disability, APOE Genotype, and Mortality: The "Treviso Longeva―Study. American Journal of Geriatric Psychiatry, 2012, 20, 594-602.	0.6	23
119	Replication Study to Confirm the Role of CYP2D6 Polymorphism rs1080985 on Donepezil Efficacy in Alzheimer's Disease Patients. Journal of Alzheimer's Disease, 2012, 30, 745-749.	1.2	35
120	Interleukin-1α, interleukin-1β and tumor necrosis factor-α genetic variants and risk of dementia in the very old: evidence from the "Monzino 80-plus―prospective study. Age, 2012, 34, 519-526.	3.0	6
121	THE TREVISO DEMENTIA (TREDEM) STUDY: A BIOMEDICAL, NEURORADIOLOGICAL, NEUROPSYCHOLOGICAL AND SOCIAL INVESTIGATION OF DEMENTIA IN NORTH-EASTERN ITALY. Journal of Frailty & Dementia in North-Eastern Italy. Journa	0.8	11
122	An APOE Haplotype Associated with Decreased $\hat{l}\mu 4$ Expression Increases the Risk of Late Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 24, 235-245.	1.2	58
123	Insulin-like growth factor 1 receptor polymorphism rs2229765 and circulating interleukin-6 level affect male longevity in a population-based prospective study (Treviso Longevaâ°' TRELONG). Aging Male, 2011, 14, 257-264.	0.9	14
124	Macroautophagy and the proteasome are differently involved in the degradation of alpha-synuclein wild type and mutated A30P in an in vitro inducible model (PC12/TetOn). Neuroscience, 2011, 195, 128-137.	1.1	26
125	A Novel Study and Meta-Analysis of the Genetic Variation of the Serotonin Transporter Promoter in the Italian Population Do Not Support a Large Effect on Alzheimer's Disease Risk. International Journal of Alzheimer's Disease, 2011, 2011, 1-7.	1.1	5
126	Nanocomposites for Neurodegenerative Diseases: Hydrogel-Nanoparticle Combinations for a Challenging Drug Delivery. International Journal of Artificial Organs, 2011, 34, 1115-1127.	0.7	52

#	Article	IF	Citations
127	Rosuvastatin and Thapsigargin Modulate $\hat{l}^3$ -Secretase Gene Expression and APP Processing in a Human Neuroglioma Model. Journal of Molecular Neuroscience, 2011, 43, 461-469.	1.1	6
128	Factors related to disability: Evidence from the "Treviso Longeva (TRELONG) Study― Archives of Gerontology and Geriatrics, 2011, 52, 309-316.	1.4	17
129	Glial Cells Drive Preconditioning-Induced Blood-Brain Barrier Protection. Stroke, 2011, 42, 1445-1453.	1.0	44
130	Vitamin B12 Levels in Alzheimer's Disease: Association with Clinical Features and Cytokine Production. Journal of Alzheimer's Disease, 2010, 19, 481-488.	1.2	39
131	Failure to Replicate an Association of rs5984894 SNP in the PCDH11X Gene in a Collection of 1,222 Alzheimer's Disease Affected Patients. Journal of Alzheimer's Disease, 2010, 21, 385-388.	1.2	11
132	Neuroprotective properties of resveratrol in different neurodegenerative disorders. BioFactors, 2010, 36, 370-376.	2.6	153
133	APOE epsilonâ€4 allele and cytokine production in Alzheimer's disease. International Journal of Geriatric Psychiatry, 2010, 25, 338-344.	1.3	33
134	Sirtuins as Novel Targets for Alzheimer's Disease and Other Neurodegenerative Disorders: Experimental and Genetic Evidence. Journal of Alzheimer's Disease, 2010, 19, 11-26.	1.2	112
135	No association between genetic markers inBDNFgene and lithium prophylaxis in a Greek sample. International Journal of Psychiatry in Clinical Practice, 2010, 14, 154-157.	1.2	7
136	The molecular genetics of sirtuins: association with human longevity and age-related diseases. International Journal of Molecular Epidemiology and Genetics, 2010, 1, 214-25.	0.4	22
137	Rs5848 Variant Influences GRN mRNA Levels in Brain and Peripheral Mononuclear Cells in Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 18, 603-612.	1.2	59
138	The Serotonin Transporter Promoter Polymorphic Region is not a Risk Factor for Alzheimer's Disease Related Behavioral Disturbances. Journal of Alzheimer's Disease, 2009, 18, 125-130.	1.2	13
139	Epistasis between IL1A, IL1B, TNF, HTR2A, 5-HTTLPR and TPH2 Variations Does Not Impact Alcohol Dependence Disorder Features. International Journal of Environmental Research and Public Health, 2009, 6, 1980-1990.	1.2	10
140	Serotonin Transporter Gene Polymorphic Element <i>5-HTTLPR</i> Increases the Risk of Sporadic Parkinson's Disease in Italy. European Neurology, 2009, 62, 120-123.	0.6	15
141	Interleukin-6 plasma level increases with age in an Italian elderly population ("The Treviso) Tj ETQq1 1 0.7843.	14 rgBT /C 3.0	Overlock 10 28
142	A polymorphic variant of the insulin-like growth factor 1 (IGF-1) receptor correlates with male longevity in the Italian population: a genetic study and evaluation of circulating IGF-1 from the "Treviso Longeva (TRELONG)" study. BMC Geriatrics, 2009, 9, 19.	1.1	28
143	The SIRT1 activator resveratrol protects SKâ∈Nâ∈BE cells from oxidative stress and against toxicity caused by αâ∈synuclein or amyloidâ∈β (1â∈42) peptide. Journal of Neurochemistry, 2009, 110, 1445-1456.	2.1	241
144	Physical activity, socialization and reading in the elderly over the age of seventy: What is the relation with cognitive decline? Evidence from "The Treviso Longeva (TRELONG) study― Archives of Gerontology and Geriatrics, 2009, 48, 284-286.	1.4	35

#	Article	IF	CITATIONS
145	TPH2 gene variants and anxiety during alcohol detoxification outcome. Psychiatry Research, 2009, 167, 106-114.	1.7	10
146	Lack of Association between Interleukin-1 alpha rs1800587 Polymorphism and Alzheimer's Disease in Two Independent European Samples. Journal of Alzheimer's Disease, 2009, 16, 181-187.	1.2	24
147	Multidisciplinary Perspectives for Alzheimer's and Parkinson's Diseases: Hydrogels for Protein Delivery and Cell-Based Drug Delivery as Therapeutic Strategies. International Journal of Artificial Organs, 2009, 32, 836-850.	0.7	48
148	Association study to evaluate the serotonin transporter and apolipoprotein E genes in frontotemporal lobar degeneration in Italy. Journal of Human Genetics, 2008, 53, 1029-1033.	1.1	8
149	Role of VEGF gene variability in longevity: A lesson from the Italian population. Neurobiology of Aging, 2008, 29, 1917-1922.	1.5	12
150	Early-Onset Alzheimer Disease in an Italian Family With Presenilin-1 Double Mutation E318G and G394V. Alzheimer Disease and Associated Disorders, 2008, 22, 184-187.	0.6	15
151	DJ-1 Modulates α-Synuclein Aggregation State in a Cellular Model of Oxidative Stress: Relevance for Parkinson's Disease and Involvement of HSP70. PLoS ONE, 2008, 3, e1884.	1.1	116
152	Presenilin-1 mutation E318G and familial Alzheimer's disease in the Italian population. Neurobiology of Aging, 2007, 28, 1682-1688.	1.5	21
153	A novel PSENEN mutation in a patient with complaints of memory loss and a family history of dementia., 2007, 3, 235-238.		8
154	The Treviso Longeva (Trelong) study: A biomedical, demographic, economic and social investigation on people 70 years and over in a typical town of North-East of Italy. Archives of Gerontology and Geriatrics, 2007, 44, 173-192.	1.4	22
155	Associations of the plasma interleukin 6 (IL-6) levels with disability and mortality in the elderly in the Treviso Longeva (Trelong) study. Archives of Gerontology and Geriatrics, 2007, 44, 193-198.	1.4	15
156	The urokinase-type plasminogen activator polymorphism PLAU_1 is a risk factor for APOE-ε4 non-carriers in the Italian Alzheimer's disease population and does not affect the plasma Aβ(1–42) level. Neurobiology of Disease, 2007, 25, 609-613.	2.1	9
157	Interleukin-1 alpha and beta, TNF-alpha and HTTLPR gene variants study on alcohol toxicity and detoxification outcome. Neuroscience Letters, 2006, 406, 107-112.	1.0	10
158	PEN–2 gene mutation in a familial Alzheimer's disease case. Journal of Neurology, 2005, 252, 1033-1036.	1.8	27
159	Genotype-Dependent Activity of Tryptophan Hydroxylase-2 Determines the Response to Citalopram in a Mouse Model of Depression. Journal of Neuroscience, 2005, 25, 8165-8172.	1.7	131
160	Rat nicastrin gene: cDNA isolation, mRNA variants and expression pattern analysis. Molecular Brain Research, 2005, 136, 12-22.	2.5	14
161	Protective effect of TATâ€delivered αâ€synuclein: relevance of the Câ€terminal domain and involvement of HSP70. FASEB Journal, 2004, 18, 1713-1715.	0.2	77
162	Dome formation in cell cultures as expression of an early stage of lactogenic differentiation of the mammary gland. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 8660-8665.	3.3	44

#	Article	lF	CITATIONS
163	In Vivo Anti-Inflammatory Effect of Statins Is Mediated by Nonsterol Mevalonate Products. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 1327-1332.	1.1	203
164	Proteomic dissection of dome formation in a mammary cell line: Role of tropomyosin-5b and maspin. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 5608-5613.	3.3	33
165	Inhibition of Monocyte Chemotactic Protein-1 Synthesis by Statins. Laboratory Investigation, 2000, 80, 1095-1100.	1.7	282
166	INHIBITION OF HMG-CoA REDUCTASE ACTIVITY BY HYPERCHOLESTEROLAEMIA REDUCES LEUKOCYTE RECRUITMENT AND MCP-1 PRODUCTION. Cytokine, 2000, 12, 1100-1103.	1.4	11
167	Alteration of SREBP Activation in Liver of Trisomy 21 Fetuses. Biochemical and Biophysical Research Communications, 1999, 260, 499-503.	1.0	12